trial · primary record
Lutetium Lu 177 Vipivotide Tetraxetan
Metastatic Castration-Resistant Prostate Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1524 |
| Primary completion | 2034-09-09 |
| Primary endpoint | Overall survival (OS) |
| Registry ID | NCT07200830 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:31.379Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07200830
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lutetium Lu-177 Vipivotide Tetraxetan · approval
- Lutetium Lu-177 Vipivotide Tetraxetan · compound